IOL Chemicals and Pharmaceuticals Limited — Investor Meet, 20-08-2026: Analysts/Institutional Investor Meet/Con. Call Updates

IOL Chemicals' Q1 FY27 results are strong: Revenue up 37% to ₹756 Cr, EBITDA up 60.7% to ₹111 Cr (14.6% margin), PAT up 89.9% to ₹64.5 Cr. Growth stems from high capacity use, better product mix & efficiency. Non-ibuprofen APIs soared 67% YoY, now 43% of pharma revenue (target 50-55% by FY29). Exports hit 28.5%. Chemical business also strong. FY27 guidance of 15-20% revenue growth, 14-15% EBITDA margin. Management is confident in sustained growth through diversification, international expansion & operational efficiency. #IOLChemicals #Earnings